{"id":46399,"date":"2025-11-11T16:49:11","date_gmt":"2025-11-11T08:49:11","guid":{"rendered":"https:\/\/flcube.com\/?p=46399"},"modified":"2025-11-11T16:49:12","modified_gmt":"2025-11-11T08:49:12","slug":"novartis-wins-fda-approval-for-remibrutinib-tablets-first-btk-inhibitor-for-chronic-spontaneous-urticaria","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46399","title":{"rendered":"Novartis Wins FDA Approval for Remibrutinib Tablets \u2013 First BTK Inhibitor for Chronic Spontaneous Urticaria"},"content":{"rendered":"\n

Novartis AG<\/strong> (NYSE: NVS<\/a>) announced that the U.S. Food and Drug Administration (FDA) has granted full approval<\/strong> to remibrutinib tablets<\/strong> for the treatment of Chronic Spontaneous Urticaria (CSU)<\/strong> in adults who remain symptomatic despite optimized H1\u2011antihistamine therapy.<\/p>\n\n\n\n

Key Deal Points<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Product<\/strong><\/td>Remibrutinib tablets (BTK inhibitor)<\/td><\/tr>
Indication<\/strong><\/td>Chronic Spontaneous Urticaria (CSU) \u2013 adults with inadequate response to H1 antihistamines<\/td><\/tr>
Regulatory Milestone<\/strong><\/td>FDA full approval<\/strong> (10\u202fNov\u202f2025)<\/td><\/tr>
First\u2011in\u2011Class<\/strong><\/td>First Bruton’s Tyrosine Kinase inhibitor (BTKi) approved for CSU<\/td><\/tr>
Dosage Form<\/strong><\/td>Oral tablet, once\u2011daily<\/td><\/tr>
Safety<\/strong><\/td>No routine laboratory monitoring required; most common AEs \u2265\u202f3\u202f%: upper\u2011respiratory infection, petechiae, headache<\/td><\/tr>
Launch Timeline<\/strong><\/td>U.S. commercial launch slated for Q1\u202f2026; global rollout to follow later in 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence<\/h2>\n\n\n\n